The Pennant Group (PNTG) Competitors

The Pennant Group (NASDAQ:PNTG) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Which has preferable earnings and valuation, PNTG or WGS?

The Pennant Group has higher revenue and earnings than GeneDx. The Pennant Group is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Pennant Group	$695.24M	1.26	$22.56M	$0.78	32.38
GeneDx	$305.45M	11.89	-$52.29M	$0.05	2,527.20

Which has more risk & volatility, PNTG or WGS?

The Pennant Group has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Does the media favor PNTG or WGS?

In the previous week, GeneDx had 6 more articles in the media than The Pennant Group. MarketBeat recorded 17 mentions for GeneDx and 11 mentions for The Pennant Group. The Pennant Group's average media sentiment score of 0.76 beat GeneDx's score of 0.75 indicating that The Pennant Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Pennant Group	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Is PNTG or WGS more profitable?

The Pennant Group has a net margin of 3.36% compared to GeneDx's net margin of 0.39%. GeneDx's return on equity of 16.51% beat The Pennant Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Pennant Group	3.36%	9.85%	4.04%
GeneDx	0.39%	16.51%	9.35%

Do analysts rate PNTG or WGS?

The Pennant Group presently has a consensus price target of $33.40, indicating a potential upside of 32.22%. GeneDx has a consensus price target of $101.63, indicating a potential downside of 19.58%. Given The Pennant Group's higher possible upside, analysts clearly believe The Pennant Group is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Pennant Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
GeneDx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders & institutionals have more ownership in PNTG or WGS?

85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 5.4% of The Pennant Group shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

GeneDx beats The Pennant Group on 9 of the 16 factors compared between the two stocks.